Latest Sales Guidance News

Atomos Limited has trimmed its FY26 sales guidance to approximately $40 million due to softer end-consumer demand and delayed product shipments, while forecasting EBITDA between $2.5 million and $3.5 million supported by improved margins.

Northern Star Resources has met its revised FY26 gold sales guidance with a strong June quarter performance and remains on track with the KCGM mill expansion. The company also announced the appointment of Suresh Vadnagra as its next CEO, effective October 2026.

TerraCom signals operational recovery with improved coal sales guidance and cost reductions at Blair Athol, while advancing leadership appointments and strategic reviews.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

New Hope Corporation lifted quarterly coal production and sales, cut sustaining capital guidance, and issued $300 million in convertible notes to extend debt maturity to 2032.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

Universal Store Holdings has posted a 14% rise in retail sales for the first 43 weeks of FY26, buoyed by strong like-for-like growth across its brands. However, ongoing wholesale challenges at CTC have triggered a $24 million impairment, even as the group maintains its full-year sales and EBITA guidance.

Nova Eye Medical reported a 23% rise in quarterly sales to US$5.8 million, driven by strong US growth and initial Chinese sales. EBITDA loss narrowed significantly, with positive operational EBITDA recorded.

Paladin Energy has lifted its uranium production guidance for FY2026 at the Langer Heinrich Mine, citing strong ramp-up progress and improved processing metrics. The company also trimmed capital expenditure forecasts while maintaining sales and cost outlooks amid geopolitical uncertainties.

Vmoto Limited forecasts FY26 sales revenue between $73.5 million and $85 million, marking a 57% to 82% increase over FY25, driven by growing orders, strategic partnerships, and regulatory trends favouring electric motorcycles in key markets.